MabVax Therapeutics Holdings Inc
MabVax Therapeutics — Investor Presentation (June 2016)
30 slides from MabVax Therapeutics's investor presentation, Jun 15, 2016
Slide 1: Immuno-Oncology Products Discovered From The Human Immune Response to Cancer
M M abVax a therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer David Hansen President and CEO June 2016 Corporate Presentation ——S
Slide 2: Disclaimer
DISCLAIMER Forward Looking Statements ‘This contains forward-looking statements and projections. ‘The company makes no express or implied representation or warranty as to the completeness of this information or, in the case of the projections, as to their attainability or the accuracy and completene
Slide 3: Key Highlights
KEY HIGHLIGHTS « HuMab Discovery Platform: antibody-based products derived from the human immune response to cancer — Developed platform for antibody discovery resulting in portfolio of fully human antibodies = Integrated approach to pment of cancer di along with thera Initial target is For pancreat
Slide 4: MabVax Discovery Platform: Therapies Derived From The Natural Human Immune Response
MABVAX DISCOVERY PLATFORM: THERAPIES DERIVED FROM THE NATURAL HUMAN IMMUNE RESPONSE | | hoc] => Focused Discovery Screening Optimized Therapy * Vaccination drives specific * Highly efficient screening + Fully human antibodies have against pre-identified targets rget * Survey response across multiple
Slide 5: HuMab-5B1 Demonstrates Integrated Antibody Clinical Development Platform
HUMAB-5B1 DEMONSTRATES INTEGRATED ANTIBODY CLINICAL DEVELOPMENT PLATFORM ‘Therapeutic Antibody (MVT-5873) 7 , tolerability as single agent ted February 2016 with early read on trial 3Q16 * Clinical Trials. gov Identifier: NCT02672917 * Clear all dosage levels for follow-on products l> Immuno-PET Ima
Slide 6: MabVax Has Rich Pipeline of Product Candidates
MABVAX Has RICH PIPELINE OF PRODUCT CANDIDATES Program Indication Collaborators 5); Pre-IND Phase1 Phase 2 iscovery ‘Commercial Rights rans MEINE PEN KG wvrses Os we ole i eee GI Cancers ww PET-Imaging SCRI, Patheon Metastatic Pancreatic MVr.1075 . Radioimmanotherapy “" KC > on Metastatic Pancreatic
Slide 7: Lead Antibody Program — HuMab-5B1
LEAD ANTIBODY PROGRAM — HUMAB-5B1 SLEA ANTIGEN EXPRESSED ON MULTIPLE SOLID TUMOR CANCERS a or HuMab-5B1 derived from a patient vaccinated . with MabVax vaccine licensed from MSKCC ii i * Patients repeatedly vaccinated to drive immune Senin response against cancer antigen 3 — 7 sin (a) « Patient samp
Slide 8: Sialyl Lewis A as a Target for Cancer Therapeutics
SIALYL LEWIS AS A TARGET FOR CANCER THERAPEUTICS + ° PS Sialyl Lewis A antigen (CA19-9) is the most frequently utilized and only validated serum marker for assessment of pancreatic cancers Expression of sLe* facilitates tumor Sia! Lewist eh proliferation, invasion, and metastatic spread! High copy n
Slide 9: HuMab-5B1 Has Ideal Characteristics That Enable Development of Product Platform
HUMAB-5B1 Has IDEAL CHARACTERISTICS THAT ENABLE DEVELOPMENT OF PRODUCT PLATFORM Character Technical Advantage of HuMal Description “Targeting cancer cell Specificity Exquisitely specific; only recognizes the target on cancer cell Binds tightly to target. Affinity Binds quickly to cancer cell and is
Slide 10: HuMab-5B1 Specificity
HUMaB-5B1 SPECIFICITY HIGHLY SPECIFIC TO sLEA ANTIGEN BY GLYCAN ARRAY ANALYSIS Exquisite binding to Sialyl Lewis A structural antigens from a database of 462 antigens! 581 (10ug/mL) Slkde# 12987 CFGH# 2008 06/25/2010 V4.1 Aloxad@8 CMZ 445000 40000 NeuSAca2-3Galf1-3(Fuca1-4)GIcNAcB, 35000 (Neu5Ac-Le?
Slide 11: HuMab-5B1 Antibody Target Significantly Overexpressed on Multiple Cancers
HUMaAsB-5Bi ANTIBODY TARGET SIGNIFICANTLY OVEREXPRESSED ON MULTIPLE CANCERS Potential therapeutic utility extends beyond pancreatic cancer . Pancreatic ductal adenocarcinoma B. Colon carcinoma . Lung adenocarcinoma . Urinary bladder, mucinous adenocarcinoma ‘. Colon metastatic to ovary ©, Breast car
Slide 12: MVT-5873 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy
MVT-5873 DEMONSTRATES SUBSTANTIAL POTENTIATION OF ANTI- TUMOR E! [ OF SOC CHEMOTHERAPY IN PANCREATIC CANCER L:fficacy evaluated as for advanced or met single agent and in combination with standard of care chemotherapy static PDAC Dose-dependent inhibition of tumor growth observed with single-agent M
Slide 13: HuMab-5B1 Demonstrates Substantial Potentiation of Anti-Tumor Effect of SOC Chemotherapy
HUMAB-5B1 DEMONSTRATES SUBSTANTIAL POTENTIATION OF ANTI- ‘TUMOR EFFECT OF SOC CHEMOTHERAPY IN PANCREATIC CANCER Relative Tumor Growth at Day 42 Gemcitabine/nab-Paclitaxel as Baseline BxPC3 Xenograft Model = 3 é = 8 2 2 2 i 6 soc SOC Plus SOC Plus SOC Plus Control MVT-5873 MVT-5873 MVT-5873 [5 mg/kg]
Slide 14: HuMab-5B1 Demonstrates Substantial Anti-Tumor Effect in Small Cell Lung Cancer Model
HUMAB-5B1 DEMONSTRATES SUBSTANTIAL ANTI-TUMOR EFFECT IN SMALL CELL LUNG CANCER MODEL oa ae Potentiation of Tumor Growth Inhibition and Growth Delay Seen When Combined With Chemotherapy 2500 P= Hu IgG 50mg/kg (control) SP MVT-5873 25 mg/kg - 2000 —S—MVT-5873 50 mg/kg — Paclitaxel 10 me/kg ¢ 1500 “~®—
Slide 15: MVT-2163 HuMab Immuno-PET Imaging Agent
MVT-2163 HUMAB IMMUNO-PET IMAGING AGENT ¢ Significant unmet medical need for improved diagnosis and monitoring of pancreatic cancer Preclinical data demonstrate potential for new HuMab-5Bibased PET agent Radiolabel abundant, commercially available, relatively inexpensive, & readily amenable to conju
Slide 16: MVT-2163 Improves Imaging Compared to Standard Agent in Use Today
MVT-2163 IMPROVES IMAGING COMPARED TO STANDARD AGENT IN USE TODAY Mice orthotopically transplanted with BxPC3-luc pancreatic tumor xenografts — The co-nghntion of FOGPET end computed Acq "Ze rioibed SB antibody (72301) soma (te) an pn eos of PET nage of te ee mone co-egitered ih icine FOG-PET only (
Slide 17: Dual Labeled HuMab-5B1 May Provide Insights During Surgical Resection
DUAL LABELED HUMAB-5B1 MAy PROVIDE INSIGHTS DURING SURGICAL RESECTION ——— — Dual labeled HuMab-5B1 (Zr & NIRP) retains targeting ability * Suite-2 tumors and metastases visualized by P and UV light surgical guidance for tamor resection can become feasible Inti J. Houghton, Site-specifically labeled
Slide 18: MVT-1075 HuMab-5B1 Radioimmunotherapy (RIT)
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY (RIT) ¢ Combines established efficacy of radiation therapy with tumor specific targeting ¢ Product has potential to deliver more potent HuMab-5B1 based product @ 'Lu isa low-energy comm emitter with a relatively short tissue penetration range 1.6 mm) p i inimizi
Slide 19: MVT-1075 Radioimmunotherapy Demonstrates Substantial Tumor Growth Suppression and Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY DEMONSTRATES SUBSTANTIAL ‘TUMOR GROWTH SUPPRESSION AND TUMOR REGRESSION * 377Lu-CHX-A"-DTPA-5B1 iodistribution of 177 Lu-CHX-A”-DTPA-5B1 N=8 for all groups Normalized Tumor Volume CPG ISA PAP? Time (days) + niin erent tom Conta (PBS) ou Preferential tumor target
Slide 20: MVT-1075 Radioimmunotherapy: Orthotopic PDAC Model Demonstrates Tumor Regression
MVT-1075 HUMAB-5B1 RADIOIMMUNOTHERAPY ORTHOTOPIC PDAC MODEL DEMONSTRATES TUMOR REGRESSION Post-1 Tumor Growth -e Control (saline) -» *7Lu-5B1 (300 iCi) Tumor Volume (mm?) C) 5 10 15 20 25 Time after RIT Administration (days) All work done in collaboration with and in the lab of Jason S, Lewis, Ph.D.
Slide 21: HuMab-5B1 Based Antibody Drug Conjugate (ADC)
HUMAB-5B1 BASED ANTIBODY DRUG CONJUGATE (ADC) « HuMab-5B1 has ideal characteristics for ADC 4 Antibody is readily internalized ¢ Large number of targets on cach cll ° Proof of concept already demonstrated « Multiple linker/toxin combinations are being evaluated to identify the best ADC candidate to
Slide 22: HuMab-5B1 ADC Demonstrates Significant Efficacy in Multiple Tumor Cell Lines
HuMas-5B1 ANTIBODY DRUG CONJUGATE DEMONSTRATES SIGNIFICANT EFFICACY IN MULTIPLE TUMOR CELL LINES pangs gyre ung capes - F : ‘ 4 Matt , i smomoonn el itp + reoesoouaiey : : wg im oo ; be i> Internalization of HuMab-5B1 s 2 Into BxPC3 Pancreatic Cancer Cells Ses - conan Pa 2: co sai as : " ay “| = ‘ma
Slide 23: HuMab-5B1 ADC In Vivo Linker Optimization Study Demonstrates Efficacy
HUMAB-5B1 ANTIBODY DRUG CONJUGATE IN VIVO LINKER OPTIMIZATION STUDY DEMONSTRATES EFFICACY 600.00 500.00 + 00 + Mean Tumor Volume P—Group 01: PBS (10mi/kg) * SBI-ADC shows dose dependent a croupon:husetaocs (ame) tumor growth ion and regression at se-croup ot: hus A0C8 (ame) higher do: o6roup 05: hus
Slide 24: HuMab-5B1 ADC Tolerability Demonstrated Across Escalating Toxin Doses
HuUMasB-5B1 ANTIBODY DRUG CONJUGATE TOLERABILITY DEMONSTRATED ACROSS ESCALATING TOXIN DOSES _ — 10 pit PBS 18 2 in TARR 300 3 ug/kg, 5 © oe g10p3 > PBS 8 100 t% Aan 150 H ugg re soe gro PBS 85 80 - Ein 0 3 6 9 1215 SC«MOg/Ag Days after treatment * Measure weight loss to determine toxicity * Weight l
Slide 25: Key Milestones for HuMab-5B1 Development Program for 2016 and 2017
Key MILESTONES FOR HUMAB5B1 DEVELOPMENT PROGRAM FOR 2016 AND 2017 HuMab-5B1 ADC Next HuMab Development Candidate M Mabyax Earlyreadouton + Complete enrollment escalation safety safety and PK read out on Phase I Trial + Initiate combo with combo with chemo chemo study trial + Initiate dose + Early re
Slide 26: Robust Intellectual Property
ROBUST INTELLECTUAL PROPERTY 4 11issued patents and 3 pending applications in the US. Issued patents covering monovalent and polyvalent vaccines, methods of manufacture, methods of use 2 pending applications covering monoclonal antibodies 4 14 international patents and 3 pending applications — Issue
Slide 27: Strong Management Team and Board of Directors
STRONG MANAGEMENT TEAM AND BOARD OF DIRECTORS J. David Hansen Founder, President && CEO ard Member Philip Livingston, M.D. Founder & Chief Science Oicer Gregory Hanson vit ent Bienes ‘Schering-Plough, Key ‘Memorial oan Kenesing Center Avani Fist Comers Wolfgang Scholz, Ph.D. Founder & Viee Paul Maff
Slide 28: Financial Information and Market Statistics
Financial Information and Market Statistics Financial Information (In Mi (As of June 43, 2016, unfess indicated otherwise) $ 5.6 Cash and cash equivalents (as of Mar. 31, 2016) $ 1.0 — Monthly burn rate $ 5.0 Debt - Oxford Finance Lic * 8 Common stock outstanding 20.7 Common equivalents - Series D &
Slide 29: Differentiated Cancer Immunotherapy Company with Multiple Near-Term Milestones
DIFFERENTIATED CANCER IMMUNOTHERAPY COMPANY WITH MULTIPLE NEAR-TERM MILESTONES ¢# Novel antibody discovery platform producing multiple novel products with significant commercial potential @ I dand yt ‘y develop strategy | ges antibodies as superior targeting agents ° HuMab-5B1 program holds sigaitto
Slide 30: Company Contacts
Mi MabVax therapeutics Immuno-Oncology Products Discovered From The Human Immune Response to Cancer Company Contacts David Hansen Gregory Hanson President and CEO Chief Financial Officer dhansen@mabv ‘om gtegoryhanson@mabv
MabVax Therapeutics Holdings — Investor Presentation (June 2016) on 6ix